Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + lenvatinib + eribulin in advanced sarcoma after first-line failure
ChiCTR2500115523Phase 2Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in leiomyosarcoma (LMS), Liposarcoma and soft tissue sarcoma (STS), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
leiomyosarcoma (LMS)Liposarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2500115523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115523.